Internship
Human Resources Alternant
School Relations & HR Projects
GE Healthcare
1-10 employees
Imaging, monitoring, and healthcare IT solutions
No salary listed
Buc, France
In Person
 People & HR (2) |
|---|
| , |
Get referred to GE Healthcare
See people who can refer or advise you
- Be a student in human resources, management, communication, or business school, or have equivalent training.
- Have a strong interest in recruitment, employer branding, and school relations.
- Be comfortable with interpersonal relations and have strong relationship-building skills.
- Be organized, autonomous, creative, and proactive.
- Be able to manage multiple projects in parallel.
- Be comfortable using digital tools, including Microsoft Office and Google Workspace; social media experience is appreciated.
- Have professional French and English proficiency in an international environment.
- Participate in defining and deploying the France school-relations strategy.
- Identify, develop, and manage partnerships with target schools, including universities, business schools, engineering schools, and specialized master's programs.
- Organize and represent GE HealthCare at school events, including forums, conferences, professional presentations, and site visits.
- Contribute to the attractiveness of work-study and internship offers and to the candidate experience.
- Animate and unite the internal network of work-study students and interns in France.
- Design and organize internal events, including onboarding, key events, professional meetings, sharing sessions, and end-of-program events.
- Contribute to national HR projects involving HR communications, employer branding, diversity and inclusion, and early careers.
- Produce internal and external communication materials, including presentations, digital content, and newsletters.
- Track and analyze key indicators related to recruitment, engagement, and satisfaction.
- A first internship or apprenticeship experience in human resources or recruitment, in an agency or within a large international company, is an asset.
- Experience with social media is appreciated.
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
- August 3, 2026 Invenia ABUS Prime targets dense-breast screening demand and remote reading.
- Tariff refunds and supply-chain shifts lifted Q2 2026 profits, while 2026 guidance stayed reaffirmed.
What critics are saying
- Patient Care Solutions fell 13.5% in Q2 2026, and management is reviewing sale options.
- CFO Jay Saccaro exits August 14, 2026, adding execution risk during the PCS review.
- Siemens Healthineers and Philips pressure GEHC in imaging; stalled innovation erodes hospital preference.
What makes GE Healthcare unique
- GE HealthCare combines imaging, pharmaceutical diagnostics, and MIM software across one workflow stack.
- Its August 2026 ABUS Prime and Allia upgrades monetize installed bases without replacements.
- FDA-cleared AI tools like ProtégéAI+ 2.0 shorten oncology workflows and deepen switching costs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.
GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.
GE HealthCare exceeded Wall Street's second-quarter profit estimates, driven by robust demand for diagnostic and imaging devices and tariff refunds from the Trump administration. The medical device maker reported net income of $561 million, up from $486 million last year, which included $129 million in tariff refunds. Revenue reached $5.30 billion for the quarter ending 30 June, surpassing the estimated $5.26 billion. Sales in imaging devices grew 7.9%, whilst pharmaceutical diagnostics jumped 15.6%. Adjusted earnings per share came in at $1.13, beating analysts' estimate of $1.04. The company's shares rose 12% in premarket trading. However, GE HealthCare noted that geopolitical instability, including Middle East conflicts, negatively affected costs, supply chains and logistics during the quarter.
GE HealthCare Technologies reported second-quarter results that exceeded Wall Street expectations. Adjusted earnings per share reached $1.13, beating the $1.04 consensus estimate, whilst revenue hit $5.3 billion, surpassing the $5.26 billion forecast and marking a 5.7% year-on-year increase. The company delivered record organic orders growth of 11.1% with a book-to-bill ratio of 1.15 times and backlog of $23.9 billion. Organic revenue grew 3.5%, driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions revenue declined 13.5% year-on-year. Adjusted EBIT margin came in at 14.2%, down 40 basis points from the prior year. Shares jumped 9% premarket following the release. GE HealthCare reaffirmed its full-year guidance, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS between $4.80 and $5.00.
GE CEO Larry Culp has orchestrated what many industry leaders consider the greatest corporate turnaround in modern business history. When he took over in 2018, GE's market capitalisation stood at $96 billion, down over 80% from its 2000 peak, with $150 billion in crushing debt. Today, the three companies Culp created from GE's breakup — GE Aerospace, GE Vernova, and GE HealthCare — have a combined market value of $689 billion. The trio has delivered annualised returns of roughly 30% since Culp's arrival, double the S&P 500's performance. GE Vernova has jumped over 600% whilst GE Aerospace has risen more than 160%. Culp's approach centred on lean manufacturing principles learnt from the Toyota Production System. He decentralised operations, eliminated three-quarters of central staff positions, and fostered a culture encouraging managers to spotlight problems rather than successes.